COMPASS Initiative
Gilead Lift
Gilead HIV Age Positively
TRANScend
HepConnect
HCV Elimination
Ebola
Grant Recipients
Grant Funding
Gilead Foundation
Gilead Public Health Award
U.S. Patient Access
Disaster Product Replacement
Global Access
Authorized Distributors
Policies
Global Transparency
Anti-Counterfeiting
Consumer Product Safety
Supplier Information
Anti-Bribery and Anti-Corruption Policy
Compassionate Use
Investigator-Sponsored Research
Clinical Trials
Press Releases
Press FAQS
Petitions to US Patent and Trademark Office on HIV PrEP Patents
Gilead Sciences Statement on U.S. Preventive Services Task Force 'A' Recommendation for PrEP as an HIV Prevention Strategy
Discount For Ambisome
Gilead 2017 Year in Review
100 Corporate Equality Score
Emergency Disaster Response
Gilead Year in Review 2016
Top Corporate Philanthropist
HIV Medicines Reach 10 Million People
Discover Study Of FTAF For PrEP
Corporate Responsibility Report 2015
Gilead Supports PrEP Education
Corporate Contributions Report
Celebrating Transgender Awareness Week
Kite Pharma
Harnessing The Immune System
Grants for SCLAN
Authorized Generics For HCV
Year in Review 2018
Cookie Statement
Website Privacy Statement
Privacy Shield Covered Entities
Linkedin Guidelines
Twitter Guidelines
Request Medication Information
Information for Suppliers
Partnership Request
Canada
Mexico
USA
Argentina
Brazil
China
Hong Kong
India
Japan
Korea
Singapore
Taiwan
United Arab Emirates
South Africa
Australia New Zealand
Austria
Belgium Luxembourg
Czech Republic & Slovakia
Denmark
Finland
France
Germany
Greece
Iceland
Ireland
Israel
Italy
Netherlands
Norway
Poland & The Baltics
Portugal
Russia
Spain
Sweden
Switzerland
Turkey
United Kingdom
Intersititial body copy
